NCT07923656Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
Study of Satellite Cells in COPD-associated sarcOPenia (Satellite Cells in COPD Sarcopenia) : Exploratory Cohort Study for Translational Research
Source: ClinicalTrials.gov · Last updated 6 Nov 2026
Brief summary (registry, in English)
The aim of the study is to decipher the alterations in signalling pathways of skeletal muscle stem cells (satellite cells (SCs)) in individuals with COPD, as well as to examine the effect of exercise training on SCs. To this end, the team will perform an exhaustive evaluation of lung and muscle function, including exercise capacity, as well as muscle biopsies, before and after a 2-months rehabilitation program. This study should provide new therapeutic avenues for COPD-associated sarcopenia.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 16 Oct 2026
- Start date
- 15 Nov 2026
- Primary completion date
- 15 Mar 2030
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- COPD
- NCT number
- NCT07923656
What you commit to
- Study type: Interventional
- Planned participants: 26
- From 15 Nov 2026 to the primary completion date, 15 Mar 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic corticosteroid therapy in progress or stopped for less than 4 weeks;
- Presence of a concomitant muscle pathology, innate (e.g., genetic myopathy) or acquired (e.g., myositis, progressive cancer);
Other illness
- Moderate or severe acute exacerbation of COPD, or acute intercurrent condition (e.g., infection) that has been ongoing or resolved for less than 4 weeks;
- Contraindication to respiratory rehabilitation: tight aortic stenosis, unstable heart failure, active thromboembolic disease, ventricular aneurysm, uncontrolled arrhythmias;
- \- Hemostasis disorders.
Lab values
- Contraindication to muscle biopsy: acquired or innate haemostasis disorders, anticoagulant treatment or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
Other
- Pregnant or breastfeeding woman;
- Patient under guardianship or curatorship;
- Refusal to participate in the study.
Who the study is looking for
- Adult male or female (age 18 years or older);
- Having a diagnosis of COPD according to the GOLD (Global Initiative for Lung Disease) 2024 criteria, i.e. a non-reversible bronchial obstruction in spirometry with a post-bronchodilator Tiffeneau coefficient \< 70%;
- Less than or equal to 75 years of age;
- Must benefit from exercise retraining sessions or respiratory rehabilitation as part of the management of COPD;
- Person affiliated to or beneficiary of a social security scheme (excluding State Medical Aid (AME));
- Free, informed and written consent signed by the participant or by a third party (in the event of the participant's physical disability) and the investigator (no later than the day of inclusion and before any review required by the research).
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Henri Mondor Coordinator of this site? Confirm its status | Créteil | France | Unknown status |
| Hopital Pitie-Salpetriere Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| CHU de Bordeaux Coordinator of this site? Confirm its status | Pessac | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.